Stock NYXH NYXH
Add to a list
To use this feature you must be a member
Log inSign up

NYXH Nasdaq

Equities

NYXH

End-of-day quote Nasdaq
Other stock markets
 		5-day change 1st Jan Change
- USD -.--% Intraday chart for NYXH -.--% -.--%
2022 Nyxoah's Q1 Loss Widens, Revenue Increases MT
2022 Oppenheimer Starts Nyxoah at Outperform With $30 Price Target MT

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration

Latest news about NYXH

Nyxoah's Q1 Loss Widens, Revenue Increases MT
Oppenheimer Starts Nyxoah at Outperform With $30 Price Target MT
Wolfe Research Starts Nyxoah at Peer Perform With $21 Price Target MT
Piper Sandler Adjusts Price Target on Nyxoah to $30 From $40, Reiterates Overweight Rating MT
NYXH : Nyxoah's Genio System Obtains CE-Mark Indication Approval to Treat Complete Concentric Collapse MT
NYXH : Nyxoah Secures Breakthrough Therapy Designation for Genio Nerve Stimulation Device MT
NYXH : Nyxoah Reports Wider Loss in H1 MT
NYXH : Stifel Initiates Nyxoah With Buy Rating MT
Sector Update: Health Care Stocks Posting Gains Ahead of Friday Close MT
Sector Update: Health Care MT
NYXH : Belgium's Nyxoah Shares Rise in Stock Market Debut MT
NYXH : Nyxoah Prices US IPO at $30 Per Share MT

Chart NYXH

Chart NYXH
More charts

Company Profile

Sector
-
More about the company
  1. Stock Market
  2. Equities
  3. NYXH Stock
  4. NYXH Stock
  5. News NYXH
  6. NYXH : Nyxoah Reports Wider Loss in H1